Aviir

Aviir, Inc. was a biotechnology firm established in 2005 by cardiologists and scientists from the Stanford University School of Medicine with a focus on developing and commercializing diagnostic tests for cardiovascular diseases. The company, headquartered in Irvine, California, aimed to reduce the impact of conditions like atherosclerosis and vascular inflammation by improving the accuracy of coronary heart disease risk assessment. Aviir operated as a venture-funded entity, securing a total of $66.7 million over 13 funding rounds, with its final Series B round in June 2013 raising $30 million, led by Merck Global Health Innovation Fund. Despite its efforts and significant financial backing, the company filed for bankruptcy in January 2014 and is now considered deadpooled.

The company's core business centered on providing advanced diagnostic laboratory tests to physicians and patients. Aviir operated its own CLIA-certified laboratory, which allowed it to offer a wide range of tests for heart health assessment and therapeutic monitoring. Its business model involved developing proprietary tests and providing them as a service through its lab, targeting physicians to aid in the early identification and prevention of cardiac events. The firm also aimed to expand its services internationally, having signed a distribution agreement for the Middle East and North Africa.

Aviir's flagship products were the MIRISK VP and TruRisk assessments, which were proprietary blood tests designed to identify individuals at high risk of experiencing a cardiac event within a five-year period. These tests utilized a proprietary biomarker panel and algorithms to assess risk factors beyond standard cholesterol levels, focusing on inflammation-mediated unstable arterial plaques. The company also developed a comprehensive menu of genetic tests for inherited cardiovascular diseases, including cardiomyopathies and arrhythmia disorders, aiming for 100% coverage of the disease-causing genes to facilitate early and effective disease management.

Keywords: cardiovascular diagnostics, diagnostic tests, heart disease prevention, biomarker panel, risk assessment, CLIA-certified laboratory, molecular diagnostics, cardiac event prediction, inherited cardiovascular disease, pharmacogenomic testing, metabolic disorders, vascular inflammation, atherosclerosis, coronary heart disease, MIRISK VP, TruRisk, Stanford University spinoff, biotechnology, venture-funded, deadpooled company